Merck, Orion join hands for Investigational Steroid Synthesis Inhibitor ODM-208 to treat Metastatic Castration-Resistant Prostate Cancer Ruchika Sharma14 July 2022 5:00 PM ISTMerck will make an upfront payment to Orion of USD 290 million, which will be expensed by Merck in the third quarter of 2022 and included in non-GAAP...
Merck in advanced talks to buy Seagen in nearly USD 40-billion deal: WSJ Ruchika Sharma10 July 2022 12:00 PM ISTThe companies are seeking to seal the deal on or before the announcement of Merck's second-quarter earnings set for July 28, according to the WSJ...
Merck launches Merck Digital Sciences Studio for healthcare startups Ruchika Sharma3 July 2022 4:00 PM ISTCurrently the program plans to include six startups at each of the Newark, NJ and Cambridge, MA venues.
Merck, Illumina launch research test to unlock deeper insights into tumor genome Ruchika Sharma25 Jun 2022 9:00 AM ISTThe Research Use Only TruSight Oncology 500 HRD test is a next-generation sequencing (NGS)–based assay.
Merck Pneumococcal 15-valent Conjugate Vaccine gets USFDA nod for pediatric use Ruchika Sharma23 Jun 2022 12:45 PM ISTRahway: Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (USFDA) has approved an...
Merck presents positive results from Pneumococcal conjugate vaccine study Ruchika Sharma22 Jun 2022 2:30 PM ISTPneumococcal disease is an infection caused by the bacterium Streptococcus pneumoniae, or pneumococcus.
Merck seeks USFDA nod for Keytruda to treat non-small cell lung cancer Ruchika Sharma14 Jun 2022 12:00 PM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
US FDA directs risk of suicide disclosure on Merck antibaldness pill Propecia Ruchika Sharma12 Jun 2022 10:55 AM ISTNew Delhi: The U.S. health regulators, the USFDA rejected a request to remove popular anti-baldness pill Propecia and its generic versions from the...
Biocytogen enters into antibody agreement with Merck Ruchika Sharma3 May 2022 9:00 AM ISTBeijing: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has announced that the company has entered into an evaluation and option agreement with Merck...
Merck KEYTRUDA gets European nod to treat Deficient Mismatch Repair tumors Ruchika Sharma2 May 2022 1:00 PM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
Merck Pneumococcal vaccine gets USFDA Breakthrough Therapy Designation Ruchika Sharma16 April 2022 12:47 PM ISTThe Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of products intended for serious or...
Merck gets positive EU CHMP opinion for Keytruda for patients with MSI-H or dMMR tumors in five different types of cancer Ruchika Sharma28 March 2022 10:30 AM ISTKeytruda is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
